O rthotopic heart transplantation (OHT) remains the operation of choice in patients with end-stage chronic heart failure. Nowadays, up to 3,800 such operations are performed annually. Only 2.7% of patients undergo transplantation as a consequence of valvular cardiomyopathy.1 In patients with rheumatic heart disease, the presence of giant left atrium (GLA) makes the technical aspects of transplantation more difficult because of substantial size mismatch between donor and recipient at the point of anastomosis. We present a rare case of OHT in a recipient with GLA. Case ReportIn July 2011, a 48-year-old man presented with an enlarged heart caused by chronic rheumatic disease (Fig. 1). His height was 174 cm and his weight was 79 kg. Twentythree years earlier, he had undergone mitral valve replacement with an EMIKS 27-mm disk graft (produced in the Union of Soviet Socialist Republics). Preoperative echocardiography showed a GLA (70 × 96 mm), with a calculated volume of 350 mL. Abdominal ultrasonic examination revealed ascites.Upon reoperative median sternotomy, we encountered intensive adhesions. After exposing the ascending aorta and the superior vena cava, we instituted partial cardiopulmonary bypass (CPB). We continued to perform cardiolysis, exposing the inferior vena cava. We then switched to full CPB with bicaval cannulation. Cardiomegaly was found, chiefly in the left atrium (LA), right atrium, and left ventricle (LV). After cross-clamping the aorta, we explanted the heart (Fig. 2). After excising the right atrium, right ventricle, and LA, we found that the remaining wall of the LA presented a particular difficulty. The residual posterior wall was considerably enlarged (18 × 16 cm) and calcified, with immovable pulmonary veins (PVs) adjoined to the surrounding tissues. After freeing the PVs, we used 2 Prolene 4-0 monofilaments on 4 × 7-mm felt pads to approximate (via gathered sutures) the ostia of the PVs laterally along the posterior wall (Fig. 3A). Each horizontal suture was located between the upper and lower PVs. These were supplemented with Prolene 4-0 sutures on felt pads introduced vertically. Placing stitches only on the posterior left atrial wall (Fig. 3B), we implanted the LA of the donor heart. All told, posterior-wall reduction and donor left atrial implantation took 57 minutes. Other anastomoses were carried out uneventfully. Cardiopulmonary bypass time was 198 min. The donor heart was anoxic for 125 min, and the operation took 299 min in total. At the end of the procedure, up to 4 L of ascitic fluid was evacuated from the abdominal cavity through the diaphragm. The patient
Актуальность проблемы лечения хронических облитерирующих заболеваний артерий нижних конечностей определяется прежде всего их распространенностью прогрессирующим течением и неудовлетворительностью результатами использования как консервативного, так и оперативного методов лечения [1-3]. В нашей стране используют классификацию хронической ишемии R. Fontaine-А.В. Покровского, по которой к критической ишемии относят ΙΙΙ стадию заболевания-боль в ноге в покое и ΙV стадию-язвенно-некротические изменения [3]. «Хроническая критическая ишемия нижних конечностей» как специальный термин впервые прозвучал в 1981 г. на Международном ангиологическом симпозиуме и в последующем упоминался C. Jamieson и соавт. [4] в работе, опубликованной в British Journal of Surgery в 1982 г. В 2007 г. на Трансатлантическом консенсусе (Inter-Society Consensus for the Management of Peripheral Arterial Disease-TASCII, 2007 г.) дано окончательное клиническое определение критической ишемии нижних конечностей (КИНК)-это персистирующая, рецидивирующая ишемическая боль, требующая постоянного адекватного обезболивания длительностью более 2 нед при снижении систолического давления в дистальной трети голени до уровня менее 50 мм рт.ст. и/или на пальцевых артериях до уровня ниже 30 мм рт.ст., либо наличие
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.